Antipsychotics work primarily by blocking dopamine receptors in the brain, reducing the overactive dopamine signaling that drives symptoms like hallucinations, delusions, and disordered thinking. This core mechanism has been the foundation of antipsychotic treatment since the 1950s, though newer drugs have added layers of complexity by targeting serotonin and other chemical messengers. The result is a class of medications that can produce noticeable improvement within the first one to two weeks, with about 68% of the total benefit on positive symptoms achieved within four weeks.
Dopamine and the Core Mechanism
The brain uses dopamine as a chemical messenger across several distinct pathways, each responsible for different functions. Antipsychotics work by attaching to dopamine receptors (specifically the D2 type) and preventing dopamine from activating them. This blockade is so central to how these drugs work that there’s an almost perfect correlation between how tightly a drug binds to D2 receptors and the dose needed to treat psychosis. D2 receptor blockade remains necessary to achieve an antipsychotic response in most patients.
The pathway that matters most for treating psychosis is the mesolimbic pathway, which runs from deep in the midbrain to areas involved in emotion, motivation, and reward. In conditions like schizophrenia, this pathway is thought to be overactive, flooding certain brain regions with too much dopamine. That excess dopamine is what produces “positive” symptoms: hearing voices, paranoid beliefs, and fragmented thinking. By dialing down dopamine activity in this pathway, antipsychotics can quiet those symptoms significantly.
The problem is that antipsychotics don’t just block dopamine in one pathway. They affect dopamine throughout the brain, which is why side effects occur. The nigrostriatal pathway, which controls movement, runs from the midbrain to areas that coordinate motor function. Blocking dopamine here can cause stiffness, tremors, and involuntary movements. Another pathway connects to the pituitary gland and regulates the hormone prolactin. Blocking dopamine there can raise prolactin levels, potentially causing breast tenderness, menstrual changes, or sexual side effects.
First-Generation vs. Second-Generation Drugs
First-generation (or “typical”) antipsychotics bind tightly to D2 dopamine receptors across the board. They’re effective at reducing hallucinations and delusions, but because they don’t discriminate between brain pathways, they carry a higher risk of movement-related side effects. The annual incidence of tardive dyskinesia, a condition involving involuntary repetitive movements (often of the face and tongue), is about 6.5% per year with first-generation drugs.
Second-generation (or “atypical”) antipsychotics take a different approach. They bind more loosely to D2 receptors and also block serotonin receptors, particularly the 5-HT2A type. This combination is what earns them the “atypical” label. The serotonin blockade appears to counterbalance some of the dopamine blockade in movement and cognition pathways, which is why these drugs tend to cause fewer movement side effects and may have modest benefits for mood and thinking. The annual rate of tardive dyskinesia drops to about 2.6% with second-generation drugs.
That serotonin-dopamine balance, however, comes with its own trade-offs, particularly metabolic ones.
Why Antipsychotics Affect Weight and Metabolism
Many second-generation antipsychotics interact with receptors for serotonin, histamine, and acetylcholine throughout the body, not just in the brain. These interactions can disrupt how your body handles fat, blood sugar, and appetite in several ways at once.
In the hypothalamus, the brain region that regulates hunger, these drugs alter appetite-controlling signals and increase sympathetic nervous system activity. This can raise levels of glucagon and increase glucose production in the liver. At the same time, serotonin receptor activity in fat tissue promotes the creation of new fat cells and the absorption of fats from the bloodstream while reducing the breakdown of stored fat. In brown fat tissue (the type that burns calories to generate heat), serotonin reduces cellular activity and energy expenditure, meaning your body burns fewer calories at rest.
Histamine receptors in muscle tissue also play a role. They influence how muscles take up glucose and store it as glycogen. Blocking these receptors alters insulin signaling pathways in ways that can lead to insulin resistance over time. Critically, these metabolic changes can appear before any noticeable weight gain, which is why blood sugar and cholesterol monitoring typically begins early in treatment. The metabolic risk varies considerably by drug. Some carry high metabolic risk, others moderate, and a few newer options appear relatively metabolically neutral.
How Quickly They Work
A common misconception is that antipsychotics take weeks to “kick in.” The evidence tells a different story. The largest improvement happens in the first two weeks of treatment, with symptom scores dropping roughly 22% to 24% in that window. The following two weeks add another 8% to 10% improvement. By the four-week mark, about 68% of the total benefit on overall symptoms and 70% of the benefit on hallucinations and delusions has already been achieved.
Full therapeutic benefit does continue to build over subsequent weeks and months, but the trajectory is clear: the drug starts working almost immediately, and the most dramatic changes come early. In clinical trials of first-episode schizophrenia patients followed for 12 months, the percentage who achieved at least a 50% reduction in symptoms ranged from 37% to 67%, depending on the specific medication used.
Why Staying on Treatment Matters
Antipsychotics manage symptoms rather than cure the underlying condition, which means stopping them carries a significant risk of relapse. One systematic review found that 77% of patients who discontinued their antipsychotic relapsed within one year, rising to 90% by two years. Even among patients who had achieved full recovery for at least a year before stopping, more than half relapsed.
This is why long-term maintenance treatment is standard for most people with schizophrenia and related conditions. The decision about how long to stay on medication involves weighing the risk of relapse against the cumulative burden of side effects, and it looks different for every person.
A New Approach Beyond Dopamine
In 2024, the FDA approved the first antipsychotic that doesn’t work through dopamine receptors at all. This drug (brand name Cobenfy) targets cholinergic receptors, part of the brain’s acetylcholine system rather than its dopamine system. It combines a compound that activates certain acetylcholine receptors in the brain with a second compound that blocks those same receptors in the rest of the body to limit side effects like nausea and excess salivation.
This approval matters because it validates a completely different theory of how psychosis can be treated. For decades, dopamine blockade was considered the only proven path to antipsychotic effect. A non-dopamine mechanism opens the door for people who don’t respond well to traditional antipsychotics or who can’t tolerate their movement-related or metabolic side effects. Early results show it can reduce symptoms of schizophrenia without the dopamine-related side effect profile that has defined this drug class for over 60 years.